GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aarti Drugs Ltd

Aarti Drugs Q2 FY27 Consolidated PAT Up 83% YoY to Rs. 82.8 Crs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 03 Nov 2026, 09:17 PM IST  ·  BSE ID: 7b196e30-b6e0-4012-a2b3-26da8b0555d3
View Original BSE Filing (PDF)
💡
In Simple Terms
Aarti Drugs announced strong financial results for the quarter ending September 2026, with profits and revenues up significantly.
🤖 AI Summary
  • Aarti Drugs' consolidated Profit After Tax (PAT) for Q2 FY27 increased 83% YoY to Rs. 82.8 Crs.
  • Consolidated Total Revenue for Q2 FY27 rose 27% YoY to Rs. 828.8 Crs.
  • Consolidated EBITDA for Q2 FY27 grew 63% YoY to Rs. 137.9 Crs, with EBITDA margin at 16.6%.
  • Specialty Chemicals segment revenue surged 92% YoY to Rs. 71.8 Crs in Q2 FY27.
  • Formulation segment revenue increased 58% YoY to Rs. 130.0 Crs in Q2 FY27.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total Revenue Q2 FY27
828.8 Rs. Crs
27%
EBITDA Q2 FY27
137.9 Rs. Crs
63%
EBITDA Margin Q2 FY27
16.6%
370 bps
Profit After Tax (PAT) Q2 FY27
82.8 Rs. Crs
83%
PAT Margin Q2 FY27
10.0%
310 bps
EPS Q2 FY27
9.07 Rs.
83%
Specialty Chemicals Revenue Q2 FY27
71.8 Rs. Crs
92%
Formulation Revenue Q2 FY27
130.0 Rs. Crs
58%
🏢 How This Affects the Company
📈
Business Impact
The company reported its highest-ever quarterly revenue from operations and EBITDA, driven by volume growth and strong realisations across API, Formulations, and Specialty Chemicals segments. The Sayakha facility scaling up has enhanced cost competitiveness in the anti-diabetic segment by meeting metformin intermediate requirements in-house.
💰
Financial Impact
Consolidated PAT grew 83% YoY to Rs. 82.8 Crs, with PAT margin expanding 310 bps to 10.0%. EBITDA margin expanded 370 bps YoY to 16.6%, reaching the highest level in nearly six years.
⚙️
Operational Impact
All manufacturing facilities operated without disruption, ensuring reliable customer service. Capacity expansions at Tarapur, Sarigam, and Baddi, including new USFDA-compliant capacity, are progressing to deepen presence in regulated markets.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results announcement.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, which showed consolidated PAT up 83% YoY to Rs. 82.8 Crs and EPS up 83% to Rs. 9.07 in Q2 FY27.
🔍
Management Signal
The management's statements indicate a focus on improving capacity utilization, expanding regulatory footprint, and driving sustainable, integrated growth following a leadership transition.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor consolidated revenue and profit growth trends.
Updates on capacity expansion projects at Tarapur, Sarigam, and Baddi.
Details on export market performance for standalone and formulation segments.
LOW RISK The filing reports strong financial performance and operational stability with leadership transition completed.
💡 Investor Takeaway
Aarti Drugs reported robust Q2 FY27 consolidated financial results, with Total Revenue at Rs. 828.8 Crs (up 27% YoY) and PAT at Rs. 82.8 Crs (up 83% YoY). EBITDA margin expanded 370 bps to 16.6%, indicating improved operational efficiency.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated PAT increased 83% YoY to Rs. 82.8 Crs in Q2 FY27, alongside a 310 bps expansion in PAT margin to 10.0%.
  • Specialty Chemicals segment revenue grew 92% YoY to Rs. 71.8 Crs, while Formulation revenue increased 58% YoY to Rs. 130.0 Crs in Q2 FY27.

⚠️ Concerns

  • Standalone export revenue declined by 5% YoY in Q2 FY27, while domestic revenue grew 43% YoY.
  • Intermediates & Others segment revenue decreased by 15% QoQ to Rs. 19.9 Crs in Q2 FY27.
📅 Company Track Record
Aarti Drugs' Q2 FY27 consolidated profit increased 83.27% YoY to Rs. 8,277 lakhs (equivalent to Rs. 82.77 Crs), as per a past filing. Q1 FY27 consolidated revenue was Rs. 703.6 Crs with PAT of Rs. 50.1 Crs, indicating growth in Q2 FY27 over Q1 FY27 as well.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Aarti Drugs' consolidated PAT in Q2 FY27?
Aarti Drugs reported a consolidated Profit After Tax (PAT) of Rs. 82.8 Crs for Q2 FY27, an increase of 83% compared to Rs. 45.2 Crs in Q2 FY26.
What was Aarti Drugs' total consolidated revenue in Q2 FY27?
The consolidated Total Revenue for Aarti Drugs in Q2 FY27 stood at Rs. 828.8 Crs, reflecting a growth of 27% YoY from Rs. 652.9 Crs in Q2 FY26.
How did Aarti Drugs' EBITDA perform in Q2 FY27?
Aarti Drugs' consolidated EBITDA was Rs. 137.9 Crs in Q2 FY27, a 63% YoY growth from Rs. 84.4 Crs in Q2 FY26. The EBITDA margin expanded to 16.6%.
Which segments showed significant growth for Aarti Drugs in Q2 FY27?
The Specialty Chemicals segment revenue grew 92% YoY to Rs. 71.8 Crs, and the Formulation segment revenue increased 58% YoY to Rs. 130.0 Crs in Q2 FY27.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.